Table 1.
Sample cohort | Assessment | |||||||
---|---|---|---|---|---|---|---|---|
Reportable range | Accuracy | Precision | Interlab concordance | Limit of detection | Extraction performance | Molecular index performance | Assay fail rate | |
Blood-derived patient samples | n/a | 376 | 271 | n/a | n/a | n/a | n/a | 30 |
Blood-derived healthy donor aliquots | 5 | n/a | 84 | 28 | 21 | 15 | 28 | 28 |
GIAB reference cell lines | 1 | 18 | n/a | n/a | 37 | n/a | 37 | 37 |
Cell lines with known HDR variants | 30 | 65 | 48 | 48 | n/a | n/a | 30 | 30 |
CDC GeT-RM PGx cell lines | 68 | 310 | 186 | 186 | n/a | n/a | 164 | 175 |
Historical blood-derived WGS data | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 25,028 |
This table summarizes the samples that were used for each set of comparisons that comprise this study. Many samples were sequenced in replicate either across the genome centers or within them and these counts reflect replicates, not unique samples
GIAB Genome in a Bottle [15], HDR hereditary disease risk, CDC United States Centers for Disease Control and Prevention, GeT-RM Genetic Testing Reference Materials Coordination Program [16], PGx pharmacogenomics, WGS whole-genome sequencing